We found that Fstl1 is evolved in the pathogenesis of liver fibrosis through a TGF-β1-miR29a-Fstl1 regulatory circuit and can serve as a therapeutic target for the treatment of liver fibrosis. This evidence concerns the gene FSTL1 and Hepatic fibrosis.